Brought to you by 
Endo gets rights to Bioniche's Urocidin; rights returned
16 Nov 2021
Executive Summary
Canadian oncology company Bioniche Life Sciences has granted Endo Pharmaceuticals (pain, urology, and cancer therapeutics) exclusive US development and marketing rights to its Urocidin for bladder cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Endo gets rights to Bioniche's Urocidin; rights returned
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice